Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease | Zendy

Laura Bauman | Zendy; Ye Xiong | Zendy; Tomoyuki Mizuno | Zendy; Philip Minar | Zendy; Tsuyoshi Fukuda | Zendy; Min Dong | Zendy; Michael J. Rosen | Zendy; Alexander A. Vinks | Zendy

Open Access

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease

Author(s) -

Laura Bauman,

Ye Xiong,

Tomoyuki Mizuno,

Philip Minar,

Tsuyoshi Fukuda,

Min Dong,

Michael J. Rosen,

Alexander A. Vinks

Publication year - 2019

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izz143

Subject(s) - medicine , infliximab , inflammatory bowel disease , population , confidence interval , dosing , erythrocyte sedimentation rate , pharmacokinetics , receiver operating characteristic , trough concentration , therapeutic drug monitoring , area under the curve , trough level , gastroenterology , disease , transplantation , environmental health , tacrolimus

Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. The object of this study was to refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research